- Home
- YHGJ vs ASBP Comparison
YHGJ vs ASBP Comparison
Compare YHGJ & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YHGJ | ASBP |
|---|---|---|
| Founded | 1975 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 7.6M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | YHGJ | ASBP |
|---|---|---|
| Price | $2.78 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.6K | ★ 529.1K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,705,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $0.47 | $0.05 |
| 52 Week High | $10.29 | $2.45 |
Technical Indicators
Market Signals| Indicator | YHGJ | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 48.74 |
| Support Level | $2.52 | $0.20 |
| Resistance Level | $3.03 | $1.29 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 28.35 | 63.60 |
Price Performance
Historical ComparisonAbout YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.